[Clinical evaluation of the therapeutic effectiveness of a new drug with anti-inflammatory-balsamic action, guacetisal, in respiratory tract diseases].
In 40 patients with bronchopulmonary diseases, in prevalence of chronic type, the therapeutic value of a new antiphlogistic-balsamic compound was evaluated. The favourable results obtained, particularly as far as the rapidity of regression of signs and symptoms is concerned, showed that this drug may have a significant role in a combined scheme of treatment.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy; D004341:Drug Evaluation; D004417:Dyspnea / Q000188:drug therapy; D005334:Fever / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012119:Respiration / Q000187:drug effects; D012140:Respiratory Tract Diseases / Q000188:drug therapy*
D001241:Aspirin; C023557:guacetisal
Valutazione clinica dell'efficacia terapeutica di un nuovo farmaco ad azione antiflogistico-balsamica, il guacetisal, nelle affezioni delle vie respiratorie.